Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Zinc pyrithione is a potent inhibitor of PL$^{Pro}$ and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
ID
Kladnik, Jerneja
(
Author
),
ID
Dolinar, Ana
(
Author
),
ID
Kljun, Jakob
(
Author
),
ID
Perea, David
(
Author
),
ID
Grau-Expósito, Judith
(
Author
),
ID
Genescà, Meritxell
(
Author
),
ID
Novinec, Marko
(
Author
),
ID
Buzon, Maria J.
(
Author
),
ID
Turel, Iztok
(
Author
)
PDF - Presentation file,
Download
(1,91 MB)
MD5: DA088CD61DFA54A238FA99B4E3C69B68
URL - Source URL, Visit
https://www.tandfonline.com/doi/full/10.1080/14756366.2022.2108417
Image galllery
Abstract
Zinc pyrithione (1a), together with its analogues 1b–h and ruthenium pyrithione complex 2a, were synthesised and evaluated for the stability in biologically relevant media and anti-SARS-CoV-2 activity. Zinc pyrithione revealed potent in vitro inhibition of cathepsin L (IC$_{50}$=1.88 ± 0.49 µM) and PL$^{Pro}$ (IC$_{50}$=0.50 ± 0.07 µM), enzymes involved in SARS-CoV-2 entry and replication, respectively, as well as antiviral entry and replication properties in an ex vivo system derived from primary human lung tissue. Zinc complexes 1b–h expressed comparable in vitro inhibition. On the contrary, ruthenium complex 2a and the ligand pyrithione a itself expressed poor inhibition in mentioned assays, indicating the importance of the selection of metal core and structure of metal complex for antiviral activity. Safe, effective, and preferably oral at-home therapeutics for COVID-19 are needed and as such zinc pyrithione, which is also commercially available, could be considered as a potential therapeutic agent against SARS-CoV-2.
Language:
English
Keywords:
antiviral agents
,
SARS-CoV-2
,
inhibition
,
pyrithione
,
zinc
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FKKT - Faculty of Chemistry and Chemical Technology
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
Str. 2158-2168
Numbering:
Vol. 37, no. 1
PID:
20.500.12556/RUL-145390
UDC:
546.47:61:577
ISSN on article:
1475-6366
DOI:
10.1080/14756366.2022.2108417
COBISS.SI-ID:
118456067
Publication date in RUL:
20.04.2023
Views:
619
Downloads:
216
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of enzyme inhibition and medicinal chemistry
Shortened title:
J. enzyme inhib. med. chem.
Publisher:
Taylor & Francis
ISSN:
1475-6366
COBISS.SI-ID:
512255001
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
protivirusna zdravila
,
SARS-COV-2
,
inhibicija
,
pirition
,
cink
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0175
Name:
Napredna anorganska kemija
Funder:
Other - Other funder or multiple funders
Funding programme:
Government of Catalonia, Health Department
Project number:
DGRIS 1_5
Funder:
Other - Other funder or multiple funders
Funding programme:
Fundació La Marató TV3
Project number:
202104FMTV3
Funder:
Other - Other funder or multiple funders
Funding programme:
Fundació La Marató TV3
Project number:
202112FMTV3
Funder:
Other - Other funder or multiple funders
Funding programme:
Spain, Health Institute Carlos III, Miguel Servet Program
Project number:
CP17/00179
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back